Treatment with an IL-17A antibody leads to the diffusion of occludin, compromising intestinal integrity, increasing gut permeability, facilitating pathogen invasion, and ultimately exacerbating colitis through the altered localization of occludin. This evidence concerns the gene OCLN and colitis.